Unknown

Dataset Information

A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model.


ABSTRACT: Dengue viruses (DENV1-4) cause 390 million clinical infections every year, several hundred thousand of which progress to severe hemorrhagic and shock syndromes. Preexisting immunity resulting from a previous DENV infection is the major risk factor for severe dengue during secondary heterologous infections. During primary infections in infants, maternal antibodies pose an analogous risk. At the same time, maternal antibodies are likely to prevent induction of endogenous anti-DENV antibodies in response to current live, attenuated virus (LAV) vaccine candidates. Any effective early life dengue vaccine has to overcome maternal antibody interference (leading to ineffective vaccination) and poor induction of antibody responses (increasing the risk of severe dengue disease upon primary infection

SUBMITTER: Khalil SM 

PROVIDER: S-EPMC4487803 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature